References

  1. Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in Schizophrenia and Schizoaffective disorder. J Clinical Psychiatry. 2010;71(suppl 2):20-6. PubMed | Google Scholar

  2. Rummel-Kluge C, Schuster T, Peters S, Kissling W. Partial compliance with antipsychotic medication is common in patients with schizophrenia. Aust N Z J Psychiatry. 2008; 42(5):382-8. PubMed | Google Scholar

  3. Masand M, Roca M, Turner M, Kane J. Partial Adherence to Antipsychotic Medication Impacts the Course of Illness in Patients With Schizophrenia: a review primary care companion. J Clinical Psychiatry. 2009; 11(4):147-54. PubMed | Google Scholar

  4. Ascher-Svanum H, Zhu B, Faries DE, Furiak NM, Montgomery W. Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia. BMC Res Notes. 2009;2:6. PubMed | Google Scholar

  5. Thieda P, Beard S, Richter A, Kane J. An economic review of com ¬pliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv. 2003;54(4):508-516. PubMed | Google Scholar

  6. Tatiana Dilla, Antonio Ciudad, María Álvarez. Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia. Dove Medical Press Patient Preference and Adherence. 2013;7: 275-284. PubMed | Google Scholar

  7. Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin. 2007;23(10):2305-2312. PubMed | Google Scholar

  8. Freudenreich O, Tranulis C. A prototype approach toward antipsychotic medication adherence in schizophrenia. Harv Rev Psychiatry. 2009;17(1):35-40. PubMed | Google Scholar

  9. Misdrahi D, Llorca PM, Lancon C, And Bayle FJ. L'observance dans la schizophr énie: facteurs prédictifs, voies de recherche, implications thérapeutiques. Encephale. 2002 ; 28 (3) : 266-72. PubMed | Google Scholar

  10. Chadzynska M, Meder J, Tyszkowska M. Compliance in the treatment of schizophrenia-project ADHES (the renewed results). Psychiatr Pol. 2008 Jul-Aug;42(4):561-70. PubMed | Google Scholar

  11. Velligan DI, Wang M, Diamond P, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv. 2007;58(9):1187-1192. PubMed | Google Scholar

  12. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998;49(2):196-201. PubMed | Google Scholar

  13. Velligan DI, Lam YW, Glahn DC, et al. Defining and assessing adher ¬ence to oral antipsychotics: a review of the literature. Schizophr Bull. 2006;32(4):724-742. PubMed | Google Scholar

  14. Sellwood W, Tarrier N, Quinn J, Barrowclough C. The family and compliance in schizophrenia: the influence of clinical variables, relatives knowledge and expressed emotion. Psychol Med. 2003; 33(1): 91-6. PubMed | Google Scholar

  15. Kampman O, Laippala P, Vaananene J,Koivisto E, Kiviniemi P,Kilkku N, Lehtinen K. Indicators of medication compliance in first-episode psychosis. Psychiatry Res. 2002;110(1): 39-48. PubMed | Google Scholar

  16. Glick ID, Stekoll AH, Hays S. The role of the family and improvement in treatment maintenance, adherence, and outcome for schizophrenia. J Clin Psychopharmacol. 2011 Feb;31(1):82-5. PubMed | Google Scholar

  17. Gilmer Todd P, Ojeda Victoria D, Barrio Concepcion, Fuentes Dahlia, Garcia Piedad, Lanouette Nicole M, Lee Kelly C. Adherence to antipsychotics among Latinos and Asians with schizophrenia and limited English proficiency. Psychiatr Serv. 2009 February ; 60(2): 175-182. PubMed | Google Scholar

  18. DiBonaventura Marco, Gabriel Susan, Dupclay Leon, Gupta1 Shaloo, Kim Edward. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012; 12:20. PubMed | Google Scholar

  19. Miller R, Ream G, McCormack J, Gunduz-Bruce H, Sevy S, Robinson D. A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia. Schizophr Res. 2009 Sep;113(2-3):138-44. PubMed | Google Scholar

  20. Buckley PF. Substance abuse in schizophrenia : a review. J Clin Psychiatry. 1998;59 (Suppl 3) : 26-30. PubMed | Google Scholar

  21. Droulout T, Liraud F, Verdoux H. Relationships between insight and medication adherence in subjects with psychosis. Encephale. 2003; 29(5): 430-7. PubMed | Google Scholar

  22. Paillot CM, Ingrand P, Ingrand I, Jaafari N. L'insight et les croyances relatives aux m édicaments influencent l'observance médicamenteuse dans la schizophénie. Annales medio-psychologiques .2011;169: 446-448.. PubMed | Google Scholar

  23. Van Putten et coll. Drug refusal in schizophrenia and the wish to be crazy. Arch Gen Psychiatry. 1974 ; 31 : 67-72. PubMed | Google Scholar

  24. Charpentier A, Goudemand M, Thomas P. Therapeutic alliance, a stake in schizophrenia. Encephale. 2009 Feb;35(1):80-9. PubMed | Google Scholar

  25. Roman B. Patients' attitudes towards generic substitution of oral atypical antipsychotics: a questionnaire-based survey in a hypothetical pharmacy setting. CNS Drugs. 2009 Aug;23(8):693-701. PubMed | Google Scholar

  26. Treur M, Heeg B, Möller HJ, Schmeding A, van Hout B. A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss. BMC Health Serv Res. 2009 Feb18;9:32. PubMed | Google Scholar

  27. Borras L, Mohr S, Brandt PY, Gilliéron C, Eytan A, Huguelet P. Religious beliefs in schizophrenia: their relevance for adherence to treatment. Schizophr Bull. 2007 Sep;33(5):1238-46. PubMed | Google Scholar

  28. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. American Journal of Psychiatry. 2004; 161(4):692-699. PubMed | Google Scholar

  29. Santé en chiffres 2011 Ministère de la santé Maroc, siteweb : santé.gov.ma(Accessed on September 15, 2013). Google Scholar

  30. Desbrus-Qochih A, Cathébras P. Obéir ou adhérer ? L'observance thérapeutique en question. Médecine & Longévité. 2012 ;4(3-4) :111-122. PubMed | Google Scholar

  31. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP. Assessment of adherence problems in patients with serious and persistent mental illness: recommendations from the Expert Consensus Guidelines. J Psychiatr Pract. 2010 Jan;16(1):34-45. PubMed | Google Scholar

  32. Barkhof E, Meijer CJ, de Sonneville LM, Linszen DH, de Haan L. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia-a review of the past decade. Eur Psychiatry. 2012 Jan;27(1):9-18. PubMed | Google Scholar

  33. Citrome L. Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia. CNS Spectr. 2012 Nov;17 (Suppl 1):1-9. PubMed | Google Scholar

  34. Pfeiffer PN, Ganoczy D, Valenstein M. Dosing frequency and adherence to antipsychotic medications. Psychiatr Serv. 2008 Oct;59(10):1207-10. PubMed | Google Scholar

  35. Schennach-Wolff R, Jäger M, Seemüller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J,Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Möller HJ, Riedel M. Attitude towards adherence in patients with schizophrenia at discharge. J Psychiatr Res. 2009 Dec;43(16):1294-301. PubMed | Google Scholar

  36. Barbui C, Kikkert M, Mazzi MA, Becker T, Bindman J, Schene A, Nos è M, Helm H, Thornicroft G, Tansella M. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence. Psychopathology. 2009;42(5):311-7. PubMed | Google Scholar

  37. Park EJ, Amatya S, Kim MS, Park JH, Seol E, Lee H, Shin YH, Na DH. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia. Arch Pharm Res. 2013 Jun;36(6):651-9. PubMed | Google Scholar

  38. Hong J, Novick D, Brugnoli R, Bertsch J, Haro JM. Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia. Hum Psychopharmacol. 2013 Jun 15 ; 25(6):439-48. PubMed | Google Scholar

  39. Novick D, Haro JM, Bertsch J, Anand H, Jemiai N, Haddad PM. Comparison of treatment discontinuation and hospitalization among nonadherent patients initiating depot or oral typical antipsychotic medications. Int Clin Psychopharmacol. 2012 Sep;27(5):275-82. PubMed | Google Scholar

  40. Liu-Seifert H, Osuntokun OO, Feldman PD. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia. Compr Psychiatry. 2012 Jan;53(1):107-15. PubMed | Google Scholar

  41. Isabelle de Beauchamp, Diane Lévy-Chavagnat, Jean-Jacques Chavagnat. Éducation thérapeutique et schizophrénie : Quels buts ? Actualités Pharmaceutiques. 2013;52 (N° 524S) :8-13. PubMed | Google Scholar

  42. Kampman O, Illi A, Poutanen P, Leinonen E. Four-year outcome in non-compliant schizophrenia patients treated with or without home-based ambulatory outpatient care. Eur Psychiatry. 2003; 18(1): 15. PubMed | Google Scholar

  43. Cañas F, Alptekin K, Azorin JM, Dubois V, Emsley R, García AG, Gorwood P, Haddad PM, Naber D, Olivares JM, Papageorgiou G, Roca M. Improving treatment adherence in your patients with schizophrenia: the STAY initiative. Clin Drug Investig. 2013 Feb;33(2):97-107. PubMed | Google Scholar